Organigram (NASDAQ:OGI – Get Free Report) is expected to release its earnings data before the market opens on Tuesday, February 11th. Analysts expect Organigram to post earnings of ($0.03) per share and revenue of $48.94 million for the quarter. Investors interested in participating in the company’s conference call can do so using this link.
Organigram (NASDAQ:OGI – Get Free Report) last posted its quarterly earnings data on Wednesday, December 18th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Organigram had a negative net margin of 28.58% and a negative return on equity of 11.68%. On average, analysts expect Organigram to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Organigram Price Performance
NASDAQ:OGI opened at $1.68 on Monday. The company has a market capitalization of $211.95 million, a P/E ratio of -4.42 and a beta of 1.00. The business has a fifty day simple moving average of $1.56 and a two-hundred day simple moving average of $1.67. Organigram has a 1 year low of $1.31 and a 1 year high of $2.91.
About Organigram
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Featured Articles
- Five stocks we like better than Organigram
- Where Do I Find 52-Week Highs and Lows?
- 3 Volatility ETFs to Help You Profit from Market Chaos
- Stock Analyst Ratings and Canadian Analyst Ratings
- Lam Research: Is a NAND Upgrade Cycle the Next Growth Catalyst?
- What is MarketRank™? How to Use it
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.